Literature DB >> 7762285

Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers.

A Kärnell1, A Li, C R Zhao, K Karlsson, B M Nguyen, A A Lindberg.   

Abstract

The live auxotrophic Shigella flexneri 2a vaccine strain SFL1070 with a deleted aroD gene was given orally to 37 adult Swedish volunteers who received three doses within 5 days. Each dose comprised 1 x 10(5) (n = 9), 1 x 10(7) (n = 10), 1 x 10(8) (n = 9) or 1 x 10(9) (n = 9) c.f.u. S. flexneri SFL1070. One volunteer vaccinated with 1 x 10(7) and three vaccinated with 1 x 10(8) c.f.u. reported mild gastrointestinal symptoms after the first dose. Vaccination with 1 x 10(9) c.f.u. caused abdominal pain and watery diarrhoea in four volunteers who all recovered spontaneously within 72 h. S. flexneri SFL1070 was not recovered from volunteers given 1 x 10(5) c.f.u., but was shed in faeces by six volunteers vaccinated with 1 x 10(7), by all nine vaccinated with 1 x 10(8), and by seven volunteers vaccinated with 1 x 10(9) c.f.u. The mean excretion time was 2.6 (range 0-4) days in the 1 x 10(8) and the 1 x 10(9) groups. Serum antibody responses against either S. flexneri 2a and Y lipopolysaccharides (LPSs) or Shigella invasion plasmid antigens (Ipa) were seen in eight volunteers vaccinated with 1 x 10(9) (p < 0.01 to p < 0.05 for mean relative titres of IgA and IgG against S. flexneri 2a and Y LPSs), in four vaccinated with 1 x 10(8), and in two and one volunteers each vaccinated with 1 x 10(7) and 1 x 10(5) c.f.u. of S. flexneri SFL1070. Intestinal sIgA responses to the same antigens were elicited in all volunteers in the 1 x 10(9) and the 1 x 10(8) groups, and in six and one volunteers vaccinated with 1 x 10(7) and 1 x 10(5) c.f.u., respectively. The sIgA responses against S. flexneri 2a and Y LPSs were significant in all but the 1 x 10(5) group (p < 0.01 to p < 0.05). Significant antibody-secreting cell (ASC) responses specific to S. flexneri 2a LPS were seen in peripheral blood from eight volunteers each in the 1 x 10(9) and 1 x 10(8) groups and from five volunteers vaccinated with 1 x 10(7) c.f.u. (p < 0.01 to p < 0.05). The number of volunteers showing anti-Shigella Ipa ASC responses in these groups were five (p < 0.01 to p < 0.05), three and one, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762285     DOI: 10.1016/0264-410x(95)80017-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.

Authors:  Yanwen Li; Yao-hui Sun; Cathy Ison; Myron M Levine; Christoph M Tang
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo.

Authors:  A Fasano; F R Noriega; F M Liao; W Wang; M M Levine
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

4.  Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.

Authors:  M T Shata; D M Hone
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Authors:  K L Kotloff; F Noriega; G A Losonsky; M B Sztein; S S Wasserman; J P Nataro; M M Levine
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

6.  Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Authors:  K L Kotloff; F R Noriega; T Samandari; M B Sztein; G A Losonsky; J P Nataro; W D Picking; E M Barry; M M Levine
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity.

Authors:  V Rasolofo-Razanamparany; A M Cassel-Beraud; J Roux; P J Sansonetti; A Phalipon
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

8.  Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants.

Authors:  A Cersini; A M Salvia; M L Bernardini
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

9.  Expression of Shigella dysenteriae serotype 1 O-antigenic polysaccharide by Shigella flexneri aroD vaccine candidates and different S. flexneri serotypes.

Authors:  I C Fält; E K Schweda; S Klee; M Singh; E Floderus; K N Timmis; A A Lindberg
Journal:  J Bacteriol       Date:  1995-09       Impact factor: 3.490

10.  Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.

Authors:  D Favre; S J Cryz; J F Viret
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.